![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BD Licenses Technology to Advance Testing for Preeclampsia, Gestational Diabetes
BD Licenses Technology to Advance Testing for Preeclampsia, Gestational Diabetes
BD has entered into a licensing and distribution agreement for clinical tests from DiabetOmics.
The company has developed new pregnancy-specific metabolic tests to provide early identification for preeclampsia and gestational diabetes. DiabetOmics has identified glycosylated fibronectin as a biological marker for the early identification of both conditions.
BD plans to create simple, affordable assays using GlyFn on its BD Veritor point-of-care diagnostic platform. BD also plans to distribute DiabetOmics’ own point-of-care tests and reader — currently in development — in select international markets. — Jonathon Shacat
Upcoming Events
-
21Oct